Item 7.01 Regulation FD Disclosure.
On August 1, 2022, Otonomy, Inc. issued a press release announcing results for
its Phase 2 clinical trial of OTO-313 in patients with tinnitus. A copy of the
press release is attached hereto as Exhibit 99.1 and incorporated herein by
All of the information furnished in this Item 7.01 and Item 9.01 (including
Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended, and shall not be incorporated
by reference in any filing under the Securities Act of 1933, as amended, or the
Securities Exchange Act of 1934, as amended, except as shall be expressly set
forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. Exhibit No. Description 99.1 Press Release dated August 1, 2022 104 Cover page interactive data file (embedded within the inline XBRL document).
© Edgar Online, source Glimpses